Professor Owen Addison Appointed to Accentus Medical Advisory Board

08 May 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce the appointment of Professor Owen Addison to the company’s Advisory Board, as Advisor on Dental Implants.

Professor Addison holds a position as Chair in Applied Biomaterials, and Honorary Consultant in Restorative Dentistry, at University of Birmingham School of Dentistry, a leading UK dental school with global academic reputation. Having completed his PhD in Biomedical Material Science in 2007, and higher clinical specialist training in Restorative Dentistry in 2012, Professor Addison is one of a very small number of dentally qualified academics to hold a National Institute of Health Research (NIHR) Clinician Scientist award. In 2013, he was awarded the International Association of Dental Research / Academy of Osseointegration Innovation in Implants Sciences Award.

Dr James Shawcross, Director of Research & Development, said: “We are delighted that Professor Addison has chosen to join our Advisory Board. Implant related infections are associated with the formation of biofilm on the surface of implanted devices. This is a global problem with socio-economic costs recognised across a range of medical device sectors. The dental implant sector is actively searching for solutions to the problem of post-operative implant infection, including peri-implantitis. With growing concern about antibiotic-resistant bacterial strains, we are commercialising our Agluna® technology as a differentiated, cost effective and clinically proven technology utilising silver ions, a well-known biocide with very limited reported bacterial resistance.”

Professor Addison commented: “The use of dental implants is increasing at a rate of at least 10% annually as a result of the rapidly growing ability of surgeons to provide implant-based solutions for patients with dental restorative needs and because of the increased patient awareness and demand for this treatment modality. Implants are however susceptible to infection related failures either in the short-term post-operatively, or associated with chronic inflammation (peri-implant disease) that develops over time. These problems have attracted considerable attention from dental clinicians and researchers because the prevalence of peri-implant disease can be as high as 12-40%. The costs of implant removal, debridement and replacement surgery are high. Agluna® technology appears to have good potential to assist in reducing the risk of dental device-related infection. There is a strong market driver for introducing a proven technology such as Agluna® to clinical adoption on dental implants. I look forward to providing clinical support and advice to the Accentus Medical team as they bring Agluna® to the dental implant market.”


For further information, please contact:
Lynne Trowbridge
T: +44 (0)20 7457 2861

Download PDF

Contact Us

T: +44 (0)1235 434 320
F: +44 (0)1235 434 329